We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+88.59%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.65B
AUM Growth
+$539M
Cap. Flow
+$95.2M
Cap. Flow %
5.75%
Top 10 Hldgs %
47.9%
Holding
83
New
24
Increased
15
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$46.6M
2
TNGX icon
Tango Therapeutics
TNGX
+$28M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
4
IMVT icon
Immunovant
IMVT
+$24.5M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.6M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$57M
2
ARVN icon
Arvinas
ARVN
+$47.5M
3
DYN icon
Dyne Therapeutics
DYN
+$21.8M
4
VSTM icon
Verastem
VSTM
+$20.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.66B
$23.1M 1.39%
+1,750,000
New +$20.6M
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$4.35B
$22.7M 1.37%
+850,000
New +$20.3M
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7.28B
$20.3M 1.23%
190,000
-10,000
-5% -$1.06M
TRVI icon
29
Trevi Therapeutics
TRVI
$2.57B
$19.4M 1.17%
1,550,000
-650,000
-30% -$7.51M
CYTK icon
30
Cytokinetics
CYTK
$10.9B
$19.1M 1.15%
+300,000
New +$18.7M
MIRM icon
31
Mirum Pharmaceuticals
MIRM
$6.96B
$17.8M 1.07%
+225,000
New +$16.1M
QURE icon
32
uniQure
QURE
$2.63B
$16.2M 0.98%
675,000
+375,000
+125% +$14.5M
NAMS icon
33
NewAmsterdam Pharma
NAMS
$3.53B
$15.8M 0.95%
+450,000
New +$16.4M
IDYA icon
34
CALL
IDEAYA Biosciences
IDYA
$3.54B
$15.6M 0.94%
450,000
– –
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$4.89B
$14.4M 0.87%
+350,000
New +$14M
SLNO
36
DELISTED
Soleno Therapeutics
SLNO
$13.9M 0.84%
+300,000
New +$16.4M
JANX icon
37
Janux Therapeutics
JANX
$950M
$13.8M 0.83%
1,000,000
+65,000
+7% +$1.53M
NERV icon
38
Minerva Neurosciences
NERV
$196M
$13.3M 0.8%
+3,311,000
New +$12.3M
VSTM icon
39
Verastem
VSTM
$534M
$13.1M 0.79%
1,700,000
-2,350,000
-58% -$20.9M
DNTH icon
40
Dianthus Therapeutics
DNTH
$5.71B
$13M 0.78%
315,000
+115,000
+58% +$4.46M
AMLX icon
41
Amylyx Pharmaceuticals
AMLX
$2.17B
$11.5M 0.69%
950,000
-500,000
-34% -$6.79M
KYMR icon
42
Kymera Therapeutics
KYMR
$9.05B
$10.1M 0.61%
130,000
-120,000
-48% -$8.1M
CLDX icon
43
Celldex Therapeutics
CLDX
$2.8B
$9.51M 0.57%
+350,000
New +$9.22M
NRIX icon
44
Nurix Therapeutics
NRIX
$2.43B
$9.48M 0.57%
+500,000
New +$7.18M
IMTX icon
45
CALL
Immatics
IMTX
$1.18B
$8.93M 0.54%
+850,000
New +$8.58M
CGON icon
46
CG Oncology
CGON
$6.48B
$8.3M 0.5%
+200,000
New +$8.28M
ACLX
47
DELISTED
Arcellx
ACLX
$7.5M 0.45%
115,000
-50,000
-30% -$3.99M
CBIO
48
Crescent Biopharma
CBIO
$626M
$7.12M 0.43%
600,000
– –
CMPX icon
49
Compass Therapeutics
CMPX
$375M
$6.18M 0.37%
1,150,000
-900,000
-44% -$4.16M
JBIO
50
Jade Biosciences
JBIO
$1.21B
$6.09M 0.37%
395,000
-230,000
-37% -$2.7M
1
2
3 4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2025 Portfolio in Review

As of Q4 2025, Logos Global Management held 83 positions worth $1.65B, up 48% from $1.12B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Logos Global Management deployed $95.2M of net new capital in Q4 2025, opening 24 new positions and adding to 15 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.8M trimmed.

  • Logos Global Management's largest Q4 2025 buy was MoonLake Immunotherapeutics: 1,750,000 shares worth $23.1M.
  • Logos Global Management added most to Praxis Precision Medicines in Q4 2025, an estimated $46.6M increase.
  • Logos Global Management's biggest Q4 2025 reduction was Dyne Therapeutics, cutting an estimated $21.8M.
  • Logos Global Management fully exited Akero Therapeutics in Q4 2025, selling an estimated $57M.
  • Logos Global Management's ten largest holdings make up 48% of its $1.65B portfolio in Q4 2025.
  • Logos Global Management opened 24 new positions and closed 14 in Q4 2025.
  • Logos Global Management's portfolio value rose 48% quarter-over-quarter to $1.65B.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.